Want to see VVOS full AI Analyst Report?
Top Page
Vivos Therapeutics
(NASDAQ:VVOS)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.14
▼(-34.55% Downside)
Action:Reiterated
Date:09/30/26
The score is held down primarily by weak financial performance—deep losses, significant cash burn, and negative equity—creating acute financing and solvency/dilution risk. Technicals also remain bearish with the stock below all key moving averages and negative MACD. The earnings call adds some support via improved revenue/gross margin trends and specific growth initiatives, but near-term liquidity constraints and NASDAQ compliance risks dominate; valuation is difficult to justify due to ongoing losses and no dividend.
Positive Factors
Revenue Growth and Gross Margin
Strong year-over-year revenue growth, together with improving gross margins, indicates increasing demand and better economics across the business. If sustained, this combination can expand the company’s revenue base and provide greater operating leverage as newer clinical services scale.
Negative Factors
Persistent Losses and Cash Burn
Vivos is generating substantial operating losses and consuming cash despite revenue growth and healthy gross margins. Continued burn reduces financial flexibility, increases dependence on outside funding, and makes the path to sustainable profitability highly dependent on successful cost control and revenue execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth and Gross Margin
Strong year-over-year revenue growth, together with improving gross margins, indicates increasing demand and better economics across the business. If sustained, this combination can expand the company’s revenue base and provide greater operating leverage as newer clinical services scale.
Read all positive factors
Vivos Therapeutics (VVOS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.00M
Dividend YieldN/A
Average Volume (3M)24.30M
Price to Earnings (P/E)―
Beta (1Y)0.44
Revenue Growth45.21%
EPS Growth-10.29%
CountryUS
Employees268
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-2.06
Shares Outstanding33,609,394
10 Day Avg. Volume9,469,668
30 Day Avg. Volume24,298,784
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)-14.00
Price to Sales (P/S)1.20
P/FCF Ratio-1.18
Enterprise Value/Market Cap3.94
Enterprise Value/Revenue0.94
Enterprise Value/Gross Profit1.58
Enterprise Value/Ebitda-0.87
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.03
Revenue Forecast (FY)$23.27M
Vivos Therapeutics Business Overview & Revenue Model
Company Description
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, ...
How the Company Makes Money
Vivos Therapeutics primarily makes money by selling products and services used by providers to deliver its sleep-disordered breathing treatment approach. Key revenue streams include: (1) revenue from the sale of oral appliance devices and related ...
Vivos Therapeutics Earnings Call Summary
Earnings Call Date:Aug 14, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 18, 2026
Earnings Call Sentiment Negative
The call presented meaningful operational progress: solid revenue growth (Q2 +35%, YTD +51%), improving gross margins, tangible contributions from the Sleep Center of Nevada (sleep testing, treatment), and multiple identified recurring-revenue initiatives (remote monitoring, DME CPAP, EEG/insomnia, pediatric program). However, material financial challenges dominate the risk profile — rising operating losses and cost of sales, heavy cash burn ($9.2M YTD), just $1.8M of cash on hand, substantial doubt about the company’s ability to continue as a going concern, and non-compliance with NASDAQ equity requirements that could trigger delisting. Management’s path to cash-flow positivity by late 2026/early 2027 is plausible but highly execution-dependent and contingent on securing additional financing. Given the severity of near-term liquidity and regulatory (NASDAQ) risks despite operational momentum, the negatives weigh heavily.Positive Updates
Quarterly and Year-to-Date Revenue Growth
Revenue for Q2 2026 was $5.2M, up $1.3M or 35% vs $3.8M in Q2 2025. Revenue for the 6 months ended June 30, 2026 was $10.3M, up $3.5M or 51% vs $6.8M in the prior-year period.
Negative Updates
Decline in Oral Appliance Product Revenue and Unit Revenue Mix
Appliance revenue fell: Q2 appliance revenue ~$1.4M (28% decrease vs prior-year Q2 $1.9M) despite selling more arches (5,180 vs 4,116), driven by a higher mix of lower-priced preformed appliances. For 6 months, arches sold increased to 10,484 but revenue decreased ~24% to $2.8M vs $3.7M prior year.
Read all updates
Q2-2026 Updates
Positive
Negative
Quarterly and Year-to-Date Revenue Growth
Revenue for Q2 2026 was $5.2M, up $1.3M or 35% vs $3.8M in Q2 2025. Revenue for the 6 months ended June 30, 2026 was $10.3M, up $3.5M or 51% vs $6.8M in the prior-year period.
Read all positive updates
Company Guidance
Management guided to a clear path to becoming cash-flow positive near the end of 2026 or in early 2027 and to generating significant positive EBITDA in fiscal 2027, supported by several quantified initiatives: an addressable remote‑patient‑monitoring pool of ~16,000 legacy CPAP patients with an estimated 5,000–7,500 enrollable over 6–12 months at net revenue of $40–$50 per patient per night; a DME CPAP program that, if scaled, could contribute roughly $150,000–$250,000 per month; Henderson capacity expanded to well over $10 million annually; an initial sleep‑optimization team serving ~250 patients/month could yield >$6 million annual revenue with contribution margins of ~40%–50%; cardiology affiliations in Arizona and Florida expected to require $0.8–$1.0 million capex each and begin generating revenue in Q1–Q2 2027—all subject to successful enrollment, reimbursement, vendor economics, payer contracting, staffing and execution (and tempered by the company’s June 30, 2026 cash balance of ~$1.8 million and need for additional financing).Vivos Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.90M | 17.44M | 15.03M | 13.80M | 16.02M | 16.89M |
| Gross Profit | 12.48M | 10.54M | 9.02M | 8.27M | 10.02M | 12.60M |
| EBITDA | -22.74M | -19.92M | -10.55M | -12.96M | -23.18M | -19.54M |
| Net Income | -25.59M | -21.23M | -11.14M | -13.58M | -23.84M | -20.29M |
Balance Sheet | ||||||
| Total Assets | 24.14M | 25.15M | 15.28M | 10.73M | 13.72M | 33.69M |
| Cash, Cash Equivalents and Short-Term Investments | 1.77M | 2.03M | 6.26M | 1.64M | 3.52M | 24.03M |
| Total Debt | 12.14M | 13.50M | 1.51M | 2.00M | 2.41M | 1.63M |
| Total Liabilities | 28.13M | 26.70M | 7.33M | 10.32M | 8.92M | 8.15M |
| Stockholders Equity | -3.81M | -1.49M | 7.95M | 411.00K | 4.80M | 25.54M |
Cash Flow | ||||||
| Free Cash Flow | -17.92M | -17.60M | -13.26M | -12.75M | -20.51M | -18.13M |
| Operating Cash Flow | -17.13M | -15.26M | -12.69M | -11.95M | -19.59M | -15.73M |
| Investing Cash Flow | -1.93M | -7.53M | -568.00K | -853.00K | -924.00K | -2.61M |
| Financing Cash Flow | 16.43M | 18.56M | 17.88M | 10.92M | 0.00 | 24.17M |
Vivos Therapeutics Technical Analysis
Negative
0.22
Price Trends
0.22
Negative
0.37
Negative
0.89
Negative
Market Momentum
-0.02
Negative
35.45
Neutral
70.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VVOS, the sentiment is Negative. The current price of 0.22 is above the 20-day moving average (MA) of 0.15, below the 50-day MA of 0.22, and below the 200-day MA of 0.89, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 35.45 is Neutral, neither overbought nor oversold. The STOCH value of 70.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VVOS.
Vivos Therapeutics Risk Analysis
Vivos Therapeutics disclosed 53 risk factors in its most recent earnings report. Vivos Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Vivos Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $15.63M | -4.38 | -78.94% | ― | 3.68% | 36.91% | |
42 Neutral | $8.34M | -0.04 | -210.99% | ― | -9.18% | 33.16% | |
42 Neutral | $2.89M | -0.09 | -661.85% | ― | -100.00% | 70.33% | |
42 Neutral | $50.91M | -0.98 | 1719.71% | ― | -6.76% | 42.70% | |
42 Neutral | $5.00M | -0.07 | 2616.82% | ― | 45.21% | -10.29% |
* Healthcare Sector Average
VVOS
Vivos Therapeutics
0.15
-3.02
-95.33%
IRIX
Iridex
0.89
-0.15
-14.42%
CODX
Co-Diagnostics
1.12
-10.42
-90.30%
ADGM
Adagio Medical Holdings
0.13
-1.78
-93.19%
COCH
Envoy Medical
0.66
-0.24
-26.84%
NXL
Nexalin Technology, Inc.
3.63
-36.57
-90.97%
Vivos Therapeutics Corporate Events
Business Operations and StrategyFinancial Disclosures
Vivos Opens New Henderson Sleep Testing and Treatment Center
Positive
Aug 21, 2026
On August 20, 2026, Vivos Therapeutics announced the grand opening of a new state-of-the-art sleep testing and treatment facility in Henderson, Nevada, under its Sleep Centers of Nevada network, with the official launch set for August 27. The cent...
Business Operations and Strategy
Vivos Therapeutics Strengthens IP for Sleep Apnea Devices
Positive
Aug 11, 2026
On August 5, 2026, Vivos Therapeutics announced the issuance of U.S. Patent No. 12,697,190, a continuation of its 2024 foundational Patent No. 12,048,608 covering its vibrational oral appliance platform with mandibular advancement technology. The ...
Executive/Board Changes
Vivos Therapeutics Appoints New Chief Financial Officer
Neutral
Aug 3, 2026
On July 31, 2026, Vivos Therapeutics’ Chief Financial Officer and Secretary, Bradford Amman, voluntarily resigned from all officer and committee positions, with the company stating the move did not stem from any disagreement over operations,...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Vivos Therapeutics Creates New Series A Preferred Stock
Positive
Jul 7, 2026
On June 30, 2026, Vivos Therapeutics raised approximately $2.1 million through a private investment in public equity, selling 3.61 million units of Series A Convertible Preferred Stock and accompanying warrants to existing investors, including an ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.